Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences
  • Register
  • Login

Urology Journal

  • Home
  • Instant Online
    • Instant 2023
    • Instant 2022
    • Instant 2021
    • Instant 2020
  • Current
  • Archives
  • Announcements
  • Submissions
  • Author Guidelines
  • About
    • About the Journal
    • Privacy Statement
    • Contact
Advanced Search
  1. Home
  2. Archives
  3. Vol. 18 No. 03 (2021): May-June 2021
  4. REVIEW

ISSN: 1735-1308

May-June 2021
Vol. 18 No. 03 (2021)

5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis

  • Yue Yang
  • Haifeng Hu
  • Hanchao Zhang
  • Zhengdao Liu
  • Faliang Zhao
  • Jin Yang
  • Guobiao Liang

Urology Journal, Vol. 18 No. 03 (2021), , Page 247-251
https://doi.org/10.22037/uj.v18i.4831 Published 11 April 2021

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Purpose: To explore the efficacy of 5-ARIs in PCA (Prostate Cancer).


Methods: Searching through the major medical databases such as PubMed, Science Citation Index, EMBASE,
Medline, Web of Science, Cochrane Library for all published studies in English until 2018. The following search
terms were used: “Finasteride”, “dutasteride”, “5α reductase inhibitors”, “5-ARIs”, “prostate cancer”, “prostate
neoplasm” and the additional related studies were manually searched. Newcastle-Ottawa Scale (NOS) assessed the qualities of studies, and the outcome measures were observed by RR or OR with 95% CIs.


Results: We included 9 eligible studies for analyses from 2011 to 2017. We found that 5-ARIs group may have
fewer progression (OR = 0.48 95%CI: 0.37-0.61 P < 0.00001, I2=4% p = 0.39) and lower pathological progression
(OR = 0.46; 95%CI: 0.29-0.73; p = 0.001, I2=0% p = 0.45), compared with control groups. However, the OS did
not show significant difference between two groups (OR=1.10; 95%CI:0.90-1.35; P = 0.35, I2 = 93% P < .00001 ).


Conclusion: The use of 5-ARIs could prevent progression in PCA patients both clinical and pathological.

Keywords:
  • Prostate Cancer
  • 4831/pdf

How to Cite

Yang, Y., Hu, H., Zhang, H., Liu, Z., Zhao, F., Yang, J., & Liang, G. (2021). 5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis. Urology Journal, 18(03), 247-251. https://doi.org/10.22037/uj.v18i.4831
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

References:

Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, et al: Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology 85:616-20, 2015

Unger JM, Hershman DL, Till C, Tangen CM, Barlow WE, Ramsey SD, Goodman PJ, Thompson IJ: Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. J Natl Cancer Inst, 2018

Murtola TJ, Kujala PM, Tammela TL: High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5alpha-reductase inhibitors and alpha-blockers. Prostate 73:923-31, 2013

Montironi R, Bartels PH, DeCensi A, Puntoni M, Hurle R, Decobelli O, Carmignani G, Mazzucchelli R, Bartels HG, et al: A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. Urol Oncol 31:557-65, 2013

Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 379:1103-11, 2012

Azoulay L, Eberg M, Benayoun S, Pollak M: 5alpha-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol 1:314-20, 2015

Dai C, Ganesan V, Zabell J, Nyame YA, Almassi N, Greene DJ, Hettel D, Reichard C, Haywood SC, et al: Impact of 5alpha-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features. J Urol 199:445-452, 2018

Schroder F, Bangma C, Angulo JC, Alcaraz A, Colombel M, McNicholas T, Tammela TL, Nandy I, Castro R: Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Cancer Study (ARTS). Eur Urol 63:779-87, 2013

Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM: Effect of treatment with 5-alpha reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU Int 110:651-7, 2012

Wong LM, Fleshner N, Finelli A: Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer: a time-dependent covariate reanalysis. Eur Urol 64:343, 2013

Kjellman A, Friis S, Granath F, Gustafsson O, Sorensen HT, Akre O: Treatment with finasteride and prostate cancer survival. Scand J Urol 47:265-71, 2013

Unger JM, Till C, Thompson IJ, Tangen CM, Goodman PJ, Wright JD, Barlow WE, Ramsey SD, Minasian LM, et al: Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 108, 2016

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, et al: Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 99:1375-83, 2007

Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE: Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 175:505-9, 2006

Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A: 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial. Int J Cancer 138:2820-8, 2016

Orsted DD, Bojesen SE, Nielsen SF, Nordestgaard BG: Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men. Eur Urol 60:691-8, 2011

  • Abstract Viewed: 0 times
  • 4831/pdf Downloaded: 0 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

In case of persistent problems in registration, primary uploading of a submission or uploading of a revision, please send us the submission files on the journal email at:

urologyjournal@sbmu.ac.ir

and please attach the screenshot of the error or problem you encountered in uploading.

 

Make a Submission

          Journal Research in Urology

Information
  • For Readers
  • For Authors
Keywords
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact
The template of this website is designed by Sinaweb